Genomics of Pulmonary Arterial Hypertension: Implications for Therapy

Overview

Journal Heart Fail Clin

Specialty Cardiology & Vascular Diseases

Date 2009 Dec 1

PMID 19945066

Citations 4

Authors

Mark W Geraci

Todd M Bull

Rubin M Tuder

Affiliations

Soon will be listed here.

Abstract

Pulmonary arterial hypertension (PAH) remains a vexing clinical disease with no cure. Despite advances and the discovery of a gene (BMPR2) associated with many of the hereditary forms of the disease, and some cases not previously known to be inherited, the reasons for mutations in this gene as a cause remain somewhat elusive. Clearly, a complex interplay exists between genetic alterations, environmental exposures (including infections), and disease development. This article addresses the advances in the genetics of PAH, including the identification of genetic etiologies and modulators, and the role of genetics in predicting disease progression and targeting therapeutics.

Citing Articles

Profile of Endothelin-1, Nitric Oxide, and Prostacyclin Levels in Pulmonary Arterial Hypertension Related to Uncorrected Atrial Septal Defect: Results from a Single Center Study in Indonesia.

Dinarti L, Hartopo A, Anggrahini D, Sadewa A, Yuli Setianto B, Wahab A Cardiol Res Pract. 2020; 2020:7526508.

PMID: 32377429 PMC: 7199565. DOI: 10.1155/2020/7526508.

Pulmonary arterial hypertension: are we close to the success?.

Rafikova O, Rafikov R J Clin Respir Med. 2019; 1(1):1-2.

PMID: 30740600 PMC: 6364833.

Early intervention in the management of pulmonary arterial hypertension: clinical and economic outcomes.

Burger C, Ghandour M, Padmanabhan Menon D, Helmi H, Benza R Clinicoecon Outcomes Res. 2017; 9:731-739.

PMID: 29200882 PMC: 5703162. DOI: 10.2147/CEOR.S119117.

Novel approaches to pulmonary arterial hypertension drug discovery.

Sung Y, Yuan K, de Jesus Perez V Expert Opin Drug Discov. 2016; 11(4):407-14.

PMID: 26901465 PMC: 4933595. DOI: 10.1517/17460441.2016.1153625.

References

Richter A, Yeager M, Zaiman A, Cool C, Voelkel N, Tuder R . Impaired transforming growth factor-beta signaling in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004; 170(12):1340-8. DOI: 10.1164/rccm.200311-1602OC. View

Pongprot Y, Sittiwangkul R, Silvilairat S, Sirisanthana V . Cardiac manifestations in HIV-infected Thai children. Ann Trop Paediatr. 2004; 24(2):153-9. DOI: 10.1179/027249304225013439. View

Linnemann T, Zheng Y, Mandic R, Peterlin B . Interaction between Nef and phosphatidylinositol-3-kinase leads to activation of p21-activated kinase and increased production of HIV. Virology. 2002; 294(2):246-55. DOI: 10.1006/viro.2002.1365. View

Lee S, Shroyer K, Markham N, Cool C, Voelkel N, Tuder R . Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest. 1998; 101(5):927-34. PMC: 508641. DOI: 10.1172/JCI1910. View

Galambos C, Montgomery J, Jenkins F . No role for kaposi sarcoma-associated herpesvirus in pediatric idiopathic pulmonary hypertension. Pediatr Pulmonol. 2005; 41(2):122-5. DOI: 10.1002/ppul.20349. View

Henke-Gendo C, Mengel M, Hoeper M, Alkharsah K, Schulz T . Absence of Kaposi's sarcoma-associated herpesvirus in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2005; 172(12):1581-5. DOI: 10.1164/rccm.200504-546OC. View

Graziani A, Galimi F, Medico E, Cottone E, Gramaglia D, Boccaccio C . The HIV-1 nef protein interferes with phosphatidylinositol 3-kinase activation 1. J Biol Chem. 1996; 271(12):6590-3. DOI: 10.1074/jbc.271.12.6590. View

Chaouat A, Coulet F, Favre C, Simonneau G, Weitzenblum E, Soubrier F . Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension. Thorax. 2004; 59(5):446-8. PMC: 1746994. DOI: 10.1136/thx.2003.11890. View

Katano H, Ito K, Shibuya K, Saji T, Sato Y, Sata T . Lack of human herpesvirus 8 infection in lungs of Japanese patients with primary pulmonary hypertension. J Infect Dis. 2005; 191(5):743-5. DOI: 10.1086/427824. View

10.

Hassoun P, Thappa V, Landman M, Fanburg B . Endothelin 1: mitogenic activity on pulmonary artery smooth muscle cells and release from hypoxic endothelial cells. Proc Soc Exp Biol Med. 1992; 199(2):165-70. DOI: 10.3181/00379727-199-43342. View

11.

Teichert-Kuliszewska K, Kutryk M, Kuliszewski M, Karoubi G, Courtman D, Zucco L . Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension. Circ Res. 2005; 98(2):209-17. DOI: 10.1161/01.RES.0000200180.01710.e6. View

12.

Remillard C, Yuan J . Activation of K+ channels: an essential pathway in programmed cell death. Am J Physiol Lung Cell Mol Physiol. 2003; 286(1):L49-67. DOI: 10.1152/ajplung.00041.2003. View

13.

Laney A, De Marco T, Peters J, Malloy M, Teehankee C, Moore P . Kaposi sarcoma-associated herpesvirus and primary and secondary pulmonary hypertension. Chest. 2005; 127(3):762-7. DOI: 10.1378/chest.127.3.762. View

14.

Galie N, Manes A, Branzi A . The endothelin system in pulmonary arterial hypertension. Cardiovasc Res. 2004; 61(2):227-37. DOI: 10.1016/j.cardiores.2003.11.026. View

15.

Heath D, Smith P, Gosney J . Ultrastructure of early plexogenic pulmonary arteriopathy. Histopathology. 1988; 12(1):41-52. DOI: 10.1111/j.1365-2559.1988.tb01915.x. View

16.

Terrier B, Tamby M, Camoin L, Guilpain P, Broussard C, Bussone G . Identification of target antigens of antifibroblast antibodies in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2008; 177(10):1128-34. DOI: 10.1164/rccm.200707-1015OC. View

17.

Bais C, Van Geelen A, Eroles P, Mutlu A, Chiozzini C, Dias S . Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/ KDR. Cancer Cell. 2003; 3(2):131-43. DOI: 10.1016/s1535-6108(03)00024-2. View

18.

Stelzner T, OBrien R, Yanagisawa M, Sakurai T, Sato K, Webb S . Increased lung endothelin-1 production in rats with idiopathic pulmonary hypertension. Am J Physiol. 1992; 262(5 Pt 1):L614-20. DOI: 10.1152/ajplung.1992.262.5.L614. View

19.

Giaid A, Yanagisawa M, Langleben D, Michel R, Levy R, Shennib H . Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993; 328(24):1732-9. DOI: 10.1056/NEJM199306173282402. View

20.

Vizza C, Letizia C, Sciomer S, Naeije R, Della Rocca G, Di Roma A . Increased plasma levels of adrenomedullin, a vasoactive peptide, in patients with end-stage pulmonary disease. Regul Pept. 2004; 124(1-3):187-93. DOI: 10.1016/j.regpep.2004.07.021. View